METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N 6‐methyladenosine‐dependent primary MicroRNA processing

Jinzhao Ma(Second Military Medical University), Fu Yang(Second Military Medical University), Chuanchuan Zhou(Second Military Medical University), Feng Liu(Second Military Medical University), Ji‐hang Yuan(Second Military Medical University), Fang Wang(Second Military Medical University), Tiantian Wang(Second Military Medical University), Qingguo Xu(Second Military Medical University), Weiping Zhou(Second Military Medical University), Shuhan Sun(Second Military Medical University)
Hepatology
October 24, 2016
Cited by 997

Abstract

N 6 ‐Methyladenosine (m 6 A) modification has been implicated in many biological processes. However, its role in cancer has not been well studied. Here, we demonstrate that m 6 A modifications are decreased in hepatocellular carcinoma, especially in metastatic hepatocellular carcinoma, and that methyltransferase‐like 14 (METTL14) is the main factor involved in aberrant m 6 A modification. Moreover, METTL14 down‐regulation acts as an adverse prognosis factor for recurrence‐free survival of hepatocellular carcinoma and is significantly associated with tumor metastasis in vitro and in vivo . We confirm that METTL14 interacts with the microprocessor protein DGCR8 and positively modulates the primary microRNA 126 process in an m 6 A‐dependent manner. Further experiments show that microRNA 126 inhibits the repressing effect of METTL14 in tumor metastasis. Conclusion : These studies reveal an important role of METTL14 in tumor metastasis and provide a fresh view on m 6 A modification in tumor progression. (H epatology 2017;65:529‐543).


Related Papers

No related papers found

Powered by citation graph analysis